Clinical Trial Update: LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating LMB-100 followed by pembrolizumab in adults with mesothelin-expressing non-squamous non-small cell lung cancer; trial status termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• LMB-100 (mesothelin-targeted immunotoxin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lung Cancer, Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-07-18